Contrasting Innovus Pharmaceuticals (INNV) & Its Rivals

Innovus Pharmaceuticals (OTCMKTS: INNV) is one of 485 publicly-traded companies in the “Pharmaceutical preparations” industry, but how does it contrast to its peers? We will compare Innovus Pharmaceuticals to related companies based on the strength of its institutional ownership, analyst recommendations, earnings, dividends, profitability, risk and valuation.

Insider & Institutional Ownership

How to Become a New Pot Stock Millionaire

46.7% of shares of all “Pharmaceutical preparations” companies are owned by institutional investors. 19.1% of Innovus Pharmaceuticals shares are owned by insiders. Comparatively, 15.6% of shares of all “Pharmaceutical preparations” companies are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Analyst Recommendations

This is a breakdown of current ratings for Innovus Pharmaceuticals and its peers, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Innovus Pharmaceuticals 0 0 0 0 N/A
Innovus Pharmaceuticals Competitors 2771 8532 21379 569 2.59

As a group, “Pharmaceutical preparations” companies have a potential upside of 44.57%. Given Innovus Pharmaceuticals’ peers higher possible upside, analysts plainly believe Innovus Pharmaceuticals has less favorable growth aspects than its peers.


This table compares Innovus Pharmaceuticals and its peers’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Innovus Pharmaceuticals -73.78% -299.94% -62.83%
Innovus Pharmaceuticals Competitors -3,094.17% -156.13% -27.37%

Earnings & Valuation

This table compares Innovus Pharmaceuticals and its peers revenue, earnings per share and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Innovus Pharmaceuticals $8.82 million -$6.50 million -3.60
Innovus Pharmaceuticals Competitors $2.03 billion $132.98 million -3.39

Innovus Pharmaceuticals’ peers have higher revenue and earnings than Innovus Pharmaceuticals. Innovus Pharmaceuticals is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.

Risk & Volatility

Innovus Pharmaceuticals has a beta of 3.96, suggesting that its share price is 296% more volatile than the S&P 500. Comparatively, Innovus Pharmaceuticals’ peers have a beta of 1.08, suggesting that their average share price is 8% more volatile than the S&P 500.


Innovus Pharmaceuticals peers beat Innovus Pharmaceuticals on 7 of the 10 factors compared.

About Innovus Pharmaceuticals

Innovus Pharmaceuticals, Inc., a pharmaceutical company, engages in the commercialization, licensing, and development of non-prescription medicine and consumer care products in the United States. Its products include Zestra, a proprietary blend of essential oils to enhance desire, arousal, and satisfaction in women; EjectDelay, an over-the-counter monograph-compliant benzocaine gel for premature ejaculation; Sensum+, a non-medicated cream that enhances penile sensitivity; Zestra Glide, a water-based longer lasting lubricant; Vesele, a proprietary oral supplement of Arginine sexual and cognitive functions; and Androferti, a natural supplement to support overall male reproductive health and sperm quality. The company also offers Beyond Human testosterone booster, Ketones, krill oil, Omega 3 fish oil, Vision Formula, blood sugar, colon cleanse, green coffee extract, and growth agent; RecalMax for brain health; and UriVarx, a proprietary supplement for overactive bladder and urinary incontinence. The company's pipeline products include FlutiCare, an over the counter drug for Rhinitis; Urocis for urinary tract infection; Xyralid, a lidocaine based cream for the relief of pain and symptoms caused by hemorrhoids; AllerVarx, a patented formulation produced in bilayer tablets; and AndroVit, a proprietary supplement to support overall prostate and male sexual health. The company markets and sells its products through commercial partners to primary care physicians, urologists, gynecologists, and therapists, as well as to other healthcare providers; and directly to consumers through online channels, retailers, and wholesalers. Innovus Pharmaceuticals, Inc. was founded in 2008 and is headquartered in San Diego, California.

Receive News & Ratings for Innovus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Innovus Pharmaceuticals and related companies with's FREE daily email newsletter.

Leave a Reply